Evidence map›Paper›PMID 31993550›Full record

ArticleJournal of the Endocrine Society2020

Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).

Nur Aisyah Zainordin, Sharifah Faradilla Wan Muhamad Hatta, Fatimah Zaherah Mohamed Shah, Thuhairah Abdul Rahman, Nurhuda Ismail, Zaliha Ismail, Rohana Abdul Ghani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nur Aisyah ZainordinEndocrine Unit, Department of Internal Medicine, Faculty of Medicine, University Teknologi MARA (UiTM), Selangor, Malaysia.ORCID 0000-0002-3970-8511
Sharifah Faradilla Wan Muhamad HattaEndocrine Unit, Department of Internal Medicine, Faculty of Medicine, University Teknologi MARA (UiTM), Selangor, Malaysia.
Fatimah Zaherah Mohamed ShahEndocrine Unit, Department of Internal Medicine, Faculty of Medicine, University Teknologi MARA (UiTM), Selangor, Malaysia.ORCID 0000-0002-7085-1092
Thuhairah Abdul RahmanPathology Diagnostic and Research Laboratories (CPDRL) Faculty of Medicine University Teknologi MARA (UiTM), Sg Buloh Campus, Selangor, Malaysia.
Nurhuda IsmailDepartment of Population Health & Preventive Medicine, Faculty of Medicine, University Teknologi MARA (UiTM), Selangor, Malaysia.
Zaliha IsmailDepartment of Population Health & Preventive Medicine, Faculty of Medicine, University Teknologi MARA (UiTM), Selangor, Malaysia.
Rohana Abdul GhaniEndocrine Unit, Department of Internal Medicine, Faculty of Medicine, University Teknologi MARA (UiTM), Selangor, Malaysia.ORCID 0000-0002-3520-8472
Universiti Teknologi MARA · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the effect of the sodium-glucose cotransporter 2 inhibitor (SGLT2-I) dapagliflozin on endothelial function in patients with high-risk type 2 diabetes mellitus (T2DM).

methodsThis was a prospective, double-blind, randomized, placebo-controlled, clinical trial of patients with T2DM with underlying ischemic heart disease who were receiving metformin and insulin therapy (n = 81). After 12-weeks of additional therapy with either dapagliflozin (n = 40) or placebo (n = 41), systemic endothelial function was evaluated by change in flow-mediated dilation (ΔFMD), change in nitroglycerin-mediated dilation (ΔNMD) and surrogate markers including intercellular adhesion molecule 1 (ICAM-1), endothelial nitric oxide synthase (eNOS), high-sensitivity C-reactive protein (hs-CRP), and lipoprotein(a) (Lp[a]). Glycemic and lipid profiles were also measured.

resultsThe dapagliflozin group demonstrated significant reductions of hemoglobin A1c (HbA1c) and fasting blood glucose (FBG) compared to the placebo group (ΔHbA1c -0.83 ± 1.47% vs -0.16 ± 1.25%,

conclusionA 12-week therapy with dapagliflozin, in addition to insulin and metformin therapies, in high-risk patients resulted in significant reductions in HbA1c, FBG, and surrogate markers of the endothelial function. Although the dapagliflozin group demonstrated a significant association between reduction in HbA1c and improvement in FMD, there was no significant difference in FMD between the 2 groups.

Identifiers

PMID31993550
PMCPMC6977943
OpenAlexW2990321183

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.